Opioid Compounding Restrictions Could Create New Headaches For FDA
Executive Summary
Advisory committee votes to add oxycodone to do-not-compound list, but will compounders now begin producing abuse-deterrent formulations?
You may also be interested in...
FDA Forced To Update Approved Products List In Do-Not-Compound Review
ANDAs mistakenly still are cataloged as approved even though they have been withdrawn from marketing.
OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting
There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.
Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon
Purdue epidemiological studies indicate reformulation of OxyContin had a positive effect on abuse and misuse of the drug, but the company says continued monitoring is needed to assess whether the positive trend continues.